Canagliflozin · Invokana

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Chronic Kidney Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
JP
  • Type 2 diabetes mellitus (Canaglu 100 mg tablets, Mitsubishi Tanabe Pharma)
Product first approved 2014daiichisankyo.com
EU
  • Type 2 diabetes mellitus (Invokana, Janssen-Cilag International NV)
Product first approved 2013EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (19)
Chronic Kidney Disease
Type 2 Diabetes
NCT04304261 · Third Military Medical University
2021-07-01 – 2024-04-30 · Diabetes Mellitus, Type 2, Cognitive Functions Confusion
What this study did
NCT02220907 · Tanabe Pharma Corporation
2014-08 – 2016-02 · Type 2 Diabetes Mellitus
What this study did
NCT02354235 · Tanabe Pharma Corporation
2015-01 – 2016-01 · Type 2 Diabetes Mellitus
What this study did
NCT01106651 · Janssen Research & Development, LLC
2010-06 – 2013-05 · Diabetes Mellitus, Type 2
What this study did
NCT01064414 · Janssen Research & Development, LLC
2010-06 – 2012-08 · Diabetes Mellitus, Type 2, Renal Insufficiency
What this study did
NCT01106690 · Janssen Research & Development, LLC
2010-06 – 2012-07 · Diabetes Mellitus, Type 2
What this study did
NCT01106677 · Janssen Research & Development, LLC
2010-05 – 2012-05 · Diabetes Mellitus, Type 2
What this study did
NCT01106625 · Janssen Research & Development, LLC
2010-05 – 2012-04 · Diabetes Mellitus, Type 2
What this study did
NCT01137812 · Janssen Research & Development, LLC
2010-07 – 2012-03 · Diabetes Mellitus, Type 2
What this study did
NCT01081834 · Janssen Research & Development, LLC
2010-03 – 2012-03 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT05364190 · October 6 University
2022-06-04 – 2024-03-01 · Chronic Heart Failure, Acute Heart Failure, Diabetes Mellitus
What this study did
NCT04252287 · Janssen Research & Development, LLC
2020-03-10 – 2021-11-09 · Heart Failure
What this study did
Phase 2/3 (1)
Type 2 Diabetes
NCT05427084 · Ottawa Heart Institute Research Corporation
2024-11-15 – 2026-12 · Diabetes Type 2, Coronary Artery Disease
What this study did
Phase 2 (12)
Chronic Kidney Disease
NCT06182839 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2024-05-01 – 2029-03-30 · ESRD, CKD Stage 4, CKD Stage 5
What this study did
NCT06913647 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2026-02-01 – 2028-12-31 · ESRD, CKD (Chronic Kidney Disease) Stage 5D
What this study did
NCT05507892 · University of Colorado, Denver
2022-10-10 – 2026-12-15 · Type 2 Diabetes, Diabetic Kidney Disease
What this study did
Type 2 Diabetes
NCT01340664 · Janssen Research & Development, LLC
2011-07 – 2012-04 · Diabetes Mellitus, Type 2
What this study did
NCT00642278 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2008-04 – 2009-01 · Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent
What this study did
Other / comorbidity
NCT07890064 · Wang Yingmei
2027-01-01 – 2031-12-31 · Endometrioid Endometrial Cancer, Atypical Endometrial Hyperplasia
What this study did
NCT06528405 · National Taiwan University Hospital
2024-11-21 – 2027-12 · Acute Kidney Injury
What this study did
NCT05090358 · Memorial Sloan Kettering Cancer Center
2021-10-08 – 2027-10-08 · Breast Cancer, Breast Cancer Stage IV, Metastatic Breast Cancer
What this study did
NCT02139943 · Janssen Research & Development, LLC
2014-05 – 2015-06 · Diabetes Mellitus, Type 1
What this study did
NCT02243202 · Janssen Research & Development, LLC
2014-09 – 2015-06 · Obesity
What this study did
NCT00650806 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2008-05 – 2008-09 · Obesity
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT04973891 · Shengjing Hospital
2021-04-07 – 2022-03-08 · Polycystic Ovary Syndrome
What this study did
NCT04073680 · Petra Pharma
2020-09-01 – 2021-12-30 · Breast Cancer, Endometrial Cancer, Lung Cancer, Colo-rectal Cancer, Head and Neck Cancer
What this study did
Phase 1 (58)
Type 2 Diabetes
NCT02891954 · University of Maryland, Baltimore
2016-09 – 2026-12-25 · Diabetes Mellitus, Type 2
What this study did
NCT02009488 · Janssen Research & Development, LLC
2014-09-08 – 2017-01-03 · Diabetes Mellitus, Type 2
What this study did
NCT02000700 · Janssen Research & Development, LLC
2014-03 – 2016-04 · Diabetes Mellitus, Type 2
What this study did
NCT01483781 · Janssen Research & Development, LLC
2011-12 – 2012-08 · Diabetes Mellitus, Type 2, Plasma Volume
What this study did
NCT01381887 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2011-06 – 2011-11 · Diabetes Mellitus, Type 2
What this study did
NCT01273558 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2011-01 – 2011-07 · Diabetes Mellitus, Type 2
What this study did
NCT01128985 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2010-03 – 2010-07 · Diabetes Mellitus, Type 2
What this study did
NCT01177163 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2008-05 – 2009-03 · Diabetes Mellitus, Type 2
What this study did
NCT00963768 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2007-06 – 2007-12 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07703163 · West China Hospital
2026-09-10 – 2028-07-31 · Solid Tumor, SGLT 2 Inhibitors
What this study did
NCT07076823 · West China Hospital
2025-07-31 – 2026-06-30 · Colorectal Cancer, SGLT-2 Inhibitor
What this study did
NCT02404870 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2014-09-16 – 2019-09-03 · Healthy Volunteers
What this study did
NCT02073227 · Janssen Research & Development, LLC
2014-02 – 2014-06 · Healthy Volunteers
What this study did
NCT02065752 · Janssen Research & Development, LLC
2014-02 – 2014-04 · Healthy Volunteers
What this study did
NCT01877889 · Janssen-Cilag International NV
2013-07 – 2014-03 · Healthy
What this study did
NCT02039245 · Janssen Research & Development, LLC
2014-01 – 2014-03 · Healthy Volunteers
What this study did
NCT02039258 · Janssen Research & Development, LLC
2014-01 – 2014-03 · Healthy Volunteers
What this study did
NCT01916863 · Lexicon Pharmaceuticals
2013-08 – 2013-10 · Healthy Subjects
What this study did
NCT01665638 · Janssen-Cilag International NV
2012-09 – 2012-10 · Healthy
What this study did
NCT01707316 · Janssen Research & Development, LLC
2012-06 – 2012-08 · Healthy
What this study did
NCT01508182 · Janssen Research & Development, LLC
2012-01 – 2012-03 · Healthy
What this study did
NCT01508195 · Janssen Research & Development, LLC
2012-01 – 2012-03 · Healthy
What this study did
NCT01428284 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2011-08 – 2011-10 · Healthy
What this study did
NCT01173549 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2010-11 – 2011-09 · Healthy
What this study did
NCT01340677 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2011-05 – 2011-08 · Healthy
What this study did
NCT01395927 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2011-07 – 2011-08 · Healthy
What this study did
NCT01294631 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2011-03 – 2011-07 · Healthy
What this study did
NCT01343290 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2011-04 – 2011-06 · Healthy
What this study did
NCT01286103 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2011-01 – 2011-05 · Healthy
What this study did
NCT01718652 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2011-02 – 2011-04 · Healthy
What this study did
NCT01281579 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2011-01 – 2011-04 · Healthy
What this study did
NCT01186588 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2010-08 – 2011-04 · Healthy, Hepatic Insufficiency
What this study did
NCT01273571 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2010-12 – 2011-02 · Healthy
What this study did
NCT01195324 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2010-09 – 2010-12 · Healthy
What this study did
NCT01157000 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2010-05 – 2010-06 · Healthy
What this study did
NCT01714206 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2009-06 – 2009-09 · Healthy
What this study did
NCT01759576 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2008-03 – 2008-11 · Renal Insufficiency, Healthy
What this study did
NCT01733108 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2008-07 – 2008-09 · Healthy
What this study did
Phase 4 (30)
Chronic Kidney Disease
NCT07547878 · Baylor Research Institute
2026-04-08 – 2029-03-31 · Chronic Kidney Disease, Type 2 Diabetes
What this study did
NCT07527390 · University Medical Center Groningen
2026-06-01 – 2027-01-30 · Dialysis, Chronic Kidney Disease (Stages 4 and 5)
What this study did
NCT05309785 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2022-11-24 – 2026-07-01 · ESRD, CKD Stage 4, CKD Stage 5
What this study did
Type 2 Diabetes
NCT07711171 · Fudan University
2024-08-19 – 2026-10-30 · Type 2 Diabetes Mellitus, Cognitive Impairment
What this study did
NCT06851962 · Fundación para la Investigación del Hospital Clínico de Valencia
2025-05-26 – 2026-06-30 · Diabetes Mellitus Type 2
What this study did
NCT05367063 · Shanghai Zhongshan Hospital
2022-01-05 – 2025-03-20 · Type 2 Diabetes, Cardiovascular Risk
What this study did
NCT04796428 · Center for Outcomes Research and Clinical Epidemiology, Italy
2021-06-30 – 2023-12-31 · Diabetes Mellitus, Type 2
What this study did
NCT02624908 · Foundation for Atlanta Veterans Education and Research, Inc.
2016-01 – 2022-12 · Diabetes Mellitus, Type 2
What this study did
NCT02653209 · Royal Devon and Exeter NHS Foundation Trust
2016-11-01 – 2021-01 · Type 2 Diabetes
What this study did
NCT02964585 · George Washington University
2016-11 – 2020-09 · Type 2 Diabetes Mellitus
What this study did
NCT04014192 · Peking Union Medical College Hospital
2019-09-01 – 2020-07-31 · Type 2 Diabetes Mellitus
What this study did
NCT03267576 · Janssen Research & Development, LLC
2017-10-27 – 2018-10-01 · Diabetes Mellitus, Type 2
What this study did
NCT02694263 · University of Leicester
2016-07 – 2018-09-13 · Diabetes Mellitus, Type 2
What this study did
NCT02920918 · Virginia Commonwealth University
2016-10 – 2018-09 · Heart Failure, Systolic, Diabetes Mellitus, Type 2
What this study did
NCT03190798 · The University of Texas Health Science Center at San Antonio
2017-09-01 – 2018-08-01 · Type2 Diabetes Mellitus, Cardiovascular Diseases
What this study did
NCT02360774 · Beth Israel Deaconess Medical Center
2015-02 – 2018-08 · Type 2 Diabetes, Overweight, Obesity
What this study did
NCT02912455 · The Cleveland Clinic
2017-01-05 – 2018-07-19 · Diabetes Mellitus, Type 2, Obesity
What this study did
NCT02597309 · Joslin Diabetes Center
2015-11 – 2017-07 · Diabetes, Obesity
What this study did
NCT01989754 · Janssen Research & Development, LLC
2014-01-16 – 2017-02-23 · Diabetes Mellitus, Type 2, Albuminuria
What this study did
NCT02142309 · University of Campania Luigi Vanvitelli
2005-10 – 2017-01 · Type 2 Diabetes
What this study did
NCT02622113 · Tanabe Pharma Corporation
2014-12 – 2016-04 · Type 2 Diabetes Mellitus
What this study did
NCT02227849 · Tanabe Pharma Corporation
2014-08 – 2016-03 · Type 2 Diabetes Mellitus
What this study did
NCT02025907 · Janssen Research & Development, LLC
2014-02 – 2015-09 · Diabetes Mellitus, Type 2
What this study did
NCT02220920 · Tanabe Pharma Corporation
2014-08 – 2015-07 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT06858436 · Taichung Veterans General Hospital
2026-04-13 – 2027-10-31 · Acute Ischemic Stroke From Large Vessel Occlusion
What this study did
NCT06256289 · Ping Li,MD
2024-03-31 – 2025-04-30 · Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease
What this study did
NCT06301529 · AgelessRx
2024-02-12 – 2024-06-29 · Healthy Aging
What this study did
NCT02462421 · University of Maryland, Baltimore
2015-06-01 – 2021-12-31 · Diabetes Mellitus, Gout, Hyperuricemia
What this study did
Early phase / not applicable (9)
Type 2 Diabetes
NCT05422092 · First Affiliated Hospital Xi'an Jiaotong University
2022-09-20 – 2023-12 · Type 2 Diabetes Mellitus With Complication
What this study did
NCT02324842 · The University of Texas Health Science Center at San Antonio
2014-11 – 2019-03-31 · Type 2 Diabetes Mellitus
What this study did
NCT03298009 · Université de Sherbrooke
2018-05-01 – 2018-06-30 · Type2 Diabetes, Heart Failure
What this study did
Other / comorbidity
NCT05903703 · Zhang Xiaofeng,MD
2023-10-01 – 2027-03-31 · Pancreatic Cancer
What this study did
NCT05135039 · xiaolong zhao
2022-01-01 – 2024-12-31 · PreDiabetes, Hiv
What this study did
NCT04720859 · Hospital Universitari Vall d'Hebron Research Institute
2018-01-05 – 2022-12-31 · Postprandial Hypoglycemia
What this study did
NCT05764811 · National Cheng-Kung University Hospital
2020-03-06 – 2022-12-31 · Fatty Liver Disease
What this study did
NCT03426956 · Hvidovre University Hospital
2018-02-08 – 2019-05-01 · Overweight
What this study did
NCT02673138 · Yale University
2016-01 – 2017-07 · Type 1 Diabetes
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Type 2 Diabetes
NCT03136484 · Novo Nordisk A/S
2017-03-15 – 2018-11-16 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Phase 4 (1)
Type 2 Diabetes
NCT05856578 · Nanjing First Hospital, Nanjing Medical University
2022-03-15 – 2023-12-31 · Type 2 Diabetes Mellitus
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Type 2 Diabetes
NCT02354222 · Tanabe Pharma Corporation
2015-01 – 2016-02 · Type 2 Diabetes Mellitus
What this study did

Competitive landscape

This mechanism is crowded: 10 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Type 2 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Canagliflozin (Invokana): this drugApprovedSmall moleculeSGLT2Partial signal
NCT03170518: Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002).
NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction
Acarbose (Precose / Glucobay)
ApprovedUS marketing discontinued
Small moleculeAlpha-glucosidasenot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01451398: Change in HbA1c from baseline to week 24: Technosphere Insulin + oral agents -0.82% (n=177) vs Technosphere powder (placebo) -0.42% (n=176); difference -0.40% (95% CI -0.57 to -0.23), p<0.0001 (CT.gov posted results).
Alogliptin (Nesina)ApprovedSmall moleculeDPP-4Partial signal
NCT02856113: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) missed
NCT00968708: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE) (From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).): Alogliptin 11.3% vs Placebo 11.8%
Bexagliflozin (Brenzavvy)ApprovedSmall moleculeSGLT2Reliable signal
NCT02769481: Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058)
NCT03259789: Change From Baseline in HbA1c at Week 24 for Double-blind Group (Baseline to week 24): Double-blind Group: Bexagliflozin 20 mg -1.09 percentage of HbA1c (Standard Error 0.076) vs Double-blind Group: Placebo -0.56 percentage of HbA1c (Standard Error 0.075)
Colesevelam (Welchol)ApprovedSmall moleculeBile acid sequestrantnot yet gradedNo reviewed efficacy summary in this indication
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Partial signal
NCT01392677: Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02)
NCT00984867: Adjusted Mean Change in HbA1c Levels (Baseline to Week 24): Dapagliflozin -0.45 Percent (95% CI -0.55 to -0.35) vs Placebo 0.04 Percent (95% CI -0.06 to 0.14)
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT03495102: Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04)
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT01131676: Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1%
NCT03429543: HbA1c change at week 26, empagliflozin pooled (10 mg and 25 mg) vs placebo: adjusted mean difference -0.84% (95% CI -1.50 to -0.19), p=0.0116. Treatment failure by week 26 in the small monotherapy cohort: 50.0% vs 60.0%, Fisher p=1.0 (CT.gov posted results).
Ertugliflozin (Steglatro)ApprovedSmall moleculeSGLT2Reliable signal
NCT01986881: Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years
NCT01958671: Change in A1C at Week 26 versus placebo: ertugliflozin 5 mg −0.99 percentage points (95% CI −1.22 to −0.76; p<0.001); ertugliflozin 15 mg −1.16 percentage points (95% CI −1.39 to −0.93; p<0.001).
Glimepiride (Amaryl)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glipizide (Glucotrol)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glyburide (DiaBeta)ApprovedSmall moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT00982644: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97)
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)Partial signal
NCT00856986: Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07)
NCT00283751: HbA1c at 52 weeks: decreased from 8.6% to 7.2% with insulin detemir vs 8.6% to 7.1% with insulin glargine (no significant difference between arms); non-inferiority of detemir to glargine demonstrated.
Insulin Efsitora Alfa (Onswik)ApprovedProtein / enzyme therapeuticInsulin receptor (basal)Partial signal
NCT05662332: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545)
NCT05275400: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority] (Baseline, Week 26): 500 U/mL - Insulin Efsitora -0.81 Percentage of HbA1c (Standard Error 0.0302) vs 100 U/mL - Insulin Degludec -0.72 Percentage of HbA1c (Standard Error 0.0424)
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)Partial signalNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT03338010: Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062)
NCT02302716: Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c) (Baseline, 24 weeks): LY2963016 -1.25 Percentage of glycosylated hemoglobin (Standard Error 0.066) vs LANTUS® -1.22 Percentage of glycosylated hemoglobin (Standard Error 0.067)
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT01499082: Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061)
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptorPartial signal
NCT00135057: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly.
Insulin Icodec (Awiqli)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT06340854: Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89)
NCT04760626: Change in Glycated Haemoglobin (HbA1c) (Baseline (week 0), week 52): Insulin Icodec -1.68 Percentage of HbA1c (Standard Error 0.09) vs Once Daily Basal Insulin Analogue -1.31 Percentage of HbA1c (Standard Error 0.12)
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptorReliable signalFeatured results are non-efficacy only in this race
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptorPartial signal
NCT03952143: Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061)
NCT03214380: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 (Baseline, Week 26): LY900014 -0.38 percentage of HbA1c (Standard Error 0.042) vs Insulin Lispro (Humalog) -0.43 percentage of HbA1c (Standard Error 0.042)
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Linagliptin (Tradjenta)ApprovedSmall moleculeDPP-4Partial signal
NCT01243424: The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years
NCT03429543: Primary HbA1c outcome at week 26: adjusted mean difference linagliptin versus placebo -0.34 percentage points (95% CI -0.99 to 0.30; p=0.2935). missed
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptorReliable signal
NCT00318461: Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07)
NCT00318422: HbA1c change from baseline at 26 weeks (added to glimepiride): liraglutide 1.2/1.8mg -1.1% (baseline 8.5%) vs placebo +0.2% (baseline 8.4%, P<0.0001) vs rosiglitazone -0.4% (baseline 8.4%, P<0.0001)
Lixisenatide (Adlyxin / Lyxumia)ApprovedPeptideGLP-1 receptorPartial signal
NCT00707031: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054)
NCT00688701: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 (Baseline, Week 12): Lixisenatide (Two-Step Titration) -0.73 percentage of hemoglobin (Standard Error 0.116) | Lixisenatide (One-Step Titration) -0.85 percentage of hemoglobin (Standard Error 0.119)
Metformin (Glucophage)
ApprovedUS marketing discontinued
Small moleculeAMPKReliable signal
NCT00004992: Diabetes incidence: 11.0 (placebo) vs 7.8 (metformin) vs 4.8 (lifestyle) cases per 100 person-years; metformin reduced incidence by 31% vs placebo (95% CI 17-43%)
Pioglitazone (Actos)ApprovedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
SAR341402ApprovedPeptideInsulin receptorPartial signal
NCT03211858: Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041)
Saxagliptin (Onglyza)
ApprovedUS marketing discontinued
Small moleculeDPP-4Reliable signal
NCT00121667: Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07)
NCT00121641: Hemoglobin A1c (A1C) Changes From Baseline at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg — Baseline Mean: 7.91 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.43 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 5 mg — Baseline Mean: 7.98 Percentage of glycosylated hemoglobins (Standard Error 0.11); Adjusted Mean Change from Baseline: -0.46 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 10 mg — Baseline Mean: 7.85 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.54 Percentage of glycosylated hemoglobins (Standard Error 0.1) vs Placebo — Baseline Mean: 7.88 Percentage of glycosylated hemoglobins (Standard Error 0.1); Adjusted Mean Change from Baseline: 0.19 Percentage of glycosylated hemoglobins (Standard Error 0.1)
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003.
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Sitagliptin (Januvia)ApprovedSmall moleculeDPP-4Partial signal
NCT00086502: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03)
NCT00087516: Change From Baseline in A1C at Week 24 (Weeks 0-24): Sitagliptin 100 mg -0.61 Percent (95% CI -0.74 to -0.49) | Sitagliptin 200 mg -0.76 Percent (95% CI -0.88 to -0.64) vs Placebo 0.18 Percent (95% CI 0.06 to 0.3)
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)Partial signal
NCT04255433: Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (From randomization (week 0) up to week 259): Tirzepatide (MTD) 801/6586 vs 1.5 mg Dulaglutide 862/6579
NCT05260021: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) (Baseline, Week 30): Pooled Doses of Tirzepatide (5 mg, 10 mg) -2.03 percentage of HbA1c (Standard Error 0.165) | Placebo -0.23 percentage of HbA1c (Standard Error 0.229)
Miglitol (Glyset)US approval withdrawnSmall moleculeAlpha-glucosidasePartial signalNo reviewed efficacy summary in this indication
Repaglinide (Prandin / NovoNorm)US approval withdrawnSmall moleculeSUR1 (short-acting)Partial signalNo reviewed efficacy summary in this indication
AlbenatidePhase 3PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
AleniglipronPhase 3Small moleculeGLP-1 receptorWeak signal
NCT05762471: Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo
Anagliptin (Suiny)Phase 3Small moleculeDPP-4Partial signal
NCT01529528: HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo.
NCT01529541: Change in HbA1c from baseline to week 24: anagliptin (CWP-0403) -0.85% vs sitagliptin -0.83%; mean difference -0.02% (95% CI -0.22 to 0.18%); non-inferiority established.
ASC30Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Berberine Ursodeoxycholate (HTD1801)Phase 3Small moleculeAMPK pathway / NLRP3 inflammasome (dual)Reliable signal
NCT06350890: SYMPHONY 1 (NCT06350890, n=408): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.3%, statistically superior to placebo
NCT06353347: SYMPHONY 2 (NCT06353347, n=551): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.2%, statistically superior to placebo
BerobenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT06897202: Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose
BGM0504Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
BofanglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
CagrilintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Cagrilintide / Semaglutide (CagriSema)Phase 3PeptideAmylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001)
NCT06534411: Primary endpoints: CagriSema 1.0 mg/1.0 mg superior to tirzepatide 5 mg for weight loss at week 60 (12.4% vs 9.1%) and non-inferior for HbA1c reduction (1.71% vs 1.67%) (2026-09-21).
Chiglitazar (Bilessglu)Phase 3Small moleculePPAR (pan-agonist)Reliable signal
NCT04807348: RECAM study, n=533 (178/177/178). LS mean change in HbA1c from baseline at Week 24: -0.91% (32mg), -1.14% (48mg), -0.49% (placebo); both doses vs placebo p<0.001; 48mg vs 32mg p=0.008.
NCT02173457: CMAS trial, primary endpoint HbA1c change from baseline at week 24: chiglitazar 32mg and 48mg both non-inferior to sitagliptin 100mg, with treatment differences of -0.04% (95% CI -0.22 to 0.15) and -0.08% (95% CI -0.27 to 0.10) vs sitagliptin (arm sizes n=245/246/248, total 739, matching this trial's design and enrollment of 740)
CofrogliptinPhase 3Small moleculeDPP-4Reliable signal
NCT04564872: HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin
NCT04556851: HbA1c change from baseline to week 24, LS mean difference vs placebo: cofrogliptin (HSK7653) 10 mg -0.63% (95% CI: -0.81, -0.46); 25 mg -0.59% (95% CI: -0.77, -0.42); both p < 0.0001
Dapagliflozin / Linagliptin (Dapalina)Phase 3Small moleculeSGLT2;DPP-4Partial signal
NCT06329674: Change in HbA1c at Week 24: -0.77% AJU-A51 vs +0.10% linagliptin+placebo; LS mean difference -0.88% (95% CI -1.07, -0.68), p<0.0001
Dorzagliatin (Huatangning)Phase 3Small moleculeGlucokinasePartial signal
NCT04531631: Acute (first-phase) insulin response to glucose, AIRg, dorzagliatin vs placebo. GCK-MODY group (n=8): 226.1 ± 64.3 vs 179.4 ± 117.7 pmol/L, P = 0.164. Type 2 diabetes group (n=10): -2.3 ± 22.6 vs 31.5 ± 22.1 pmol/L, P = 0.006 (dorzagliatin lower than placebo). missed
EcnoglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Efmedaglutide Alfa (Shanmeining)Phase 3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT06235086: Primary endpoint, HbA1c change at week 28: each TG103 dose non-inferior to dulaglutide 1.5 mg (treatment policy analysis); 15 mg lowered HbA1c 1.38% (CSPC, 2026-09-30).
EfpeglenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT03353350: Change in HbA1c from baseline to week 30 vs placebo: efpeglenatide 2 mg -0.5% (95% CI -0.9 to -0.2), p=0.0054; 4 mg -0.8% (-1.2 to -0.5), p<0.0001; 6 mg -1.0% (-1.4 to -0.7), p<0.0001 (AMPLITUDE-M, Rosenstock 2022, Diabetes Care).
Efsubaglutide AlfaPhase 3Protein / enzyme therapeuticGLP-1 receptorReliable signal
NCT04994288: HbA1c change from baseline at week 24 (SUPER-1, phase III stage): 1 mg dose -1.73% (95% CI -20.98,-16.83 mmol/mol), 3 mg dose -2.15% (95% CI -25.68,-21.31 mmol/mol); estimated treatment difference vs placebo -1.26% (1 mg, 95% CI -17.39,-10.06 mmol/mol) and -1.68% (3 mg, 95% CI -22.08,-14.64 mmol/mol), both CIs excluding zero.
NCT04998032: HbA1c change from baseline at week 24 (SUPER-2, add-on to metformin): Efsubaglutide 3 mg -1.80% vs placebo -0.74%; estimated treatment difference -1.06% (p<0.001)
ElecoglipronPhase 3Small moleculeGLP-1 receptorReliable signal
NCT06579105: HbA1c reduction over 26 weeks: 1.9% with elecoglipron 75 mg (highest dose) vs 0.2% with placebo
Enavogliflozin (Envlo)Phase 3Small moleculeSGLT2Reliable signal
NCT04634500: Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35%
NCT04632862: Placebo-adjusted mean change in HbA1c from baseline at week 24 in the enavogliflozin 0.3 mg group: -0.99% (95% confidence interval -1.24%, -0.74%).
EnicepatidePhase 3PeptideGLP-1 receptor, GLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Evogliptin (Suganon)Phase 3Small moleculeDPP-4Reliable signal
NCT04170998: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001)
NCT02949193: HbA1c change from baseline at 24 weeks: -0.59% with evogliptin 5mg (n=112) vs -0.65% with sitagliptin 100mg (n=110), both add-on to metformin; between-group difference 0.06 percentage points (95% CI -0.10 to 0.22), demonstrating non-inferiority.
Exendin-4 Fc Fusion (JY09)Phase 3Protein / enzyme therapeuticGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Gemigliptin (Zemiglo)Phase 3Small moleculeDPP-4Reliable signal
NCT03842267: LSM difference in HbA1c change at week 24 (gemigliptin add-on vs placebo, on background dapagliflozin + metformin): −0.66% (SE 0.07), 95% CI −0.80% to −0.52%.
NCT02831361: Change in HbA1c from baseline at Week 24, between-group mean difference (gemigliptin 50 mg vs placebo, added to insulin ± metformin): -0.7 percentage points (95% CI -0.9 to -0.4), p<0.0001
GosogliptinPhase 3Small moleculeDPP-4Partial signal
NCT03088670: Primary, HbA1c change at week 12 (monotherapy stage): 8.61% to 7.41% with gosogliptin vs 8.7% to 7.34% with vildagliptin (each p<0.05 vs baseline); the between-group difference was not significant and no non-inferiority test or margin is reported. Week 36 not reported. Target HbA1c <=7.0%: 41% vs 44% (p=0.53).
GZR33Phase 3PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
HenagliflozinPhase 3Small moleculeSodium-glucose cotransporter 2 (SGLT2)Reliable signal
NCT04390295: Placebo-adjusted LS mean HbA1c change at Week 24: -0.76% (5 mg) and -0.80% (10 mg) vs placebo, both P < .0001.
NCT03159052: Placebo-adjusted LS mean HbA1c change at Week 24: -0.91% (5 mg) and -0.94% (10 mg) vs placebo, both P < .001.
Janagliflozin (Huiyoujing)Phase 3Small moleculeSGLT2Reliable signal
NCT03811548: Placebo-adjusted HbA1c change at week 24: janagliflozin 25 mg -0.80% (95% CI -0.98 to -0.62), 50 mg -0.88% (95% CI -1.06 to -0.70); P<0.001 for both (Ji et al., Diabetes Obes Metab 2023)
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)Partial signal
NCT05929079: Primary endpoint, percent change in body weight from baseline to week 80 (treatment-regimen estimand): retatrutide 9 mg -16.8% and 12 mg -18.8% vs placebo -5.1%; treatment differences -11.8% (95% CI -13.7 to -9.8) and -13.8% (95% CI -15.8 to -11.8); p<0.0001 for both, met. Key secondary, 4 mg vs placebo: -11.9% vs -5.1% (difference -6.9%, 95% CI -8.7 to -5.1; p<0.0001). The registered AHI primary in the sleep apnea subset is not reported in the paper abstract.
NCT06354660: Change in HbA1c from baseline (7.9%) at Week 40: 4 mg -1.7%, 9 mg -2.0%, 12 mg -1.9%, placebo -0.8%; retatrutide met the primary endpoint.
Safiglipron (HRS-7535)Phase 3Small moleculeGLP-1 receptorPartial signal
NCT06589765: Primary, HbA1c change from baseline at week 32 vs dapagliflozin 10 mg (non-inferiority margin 0.4%, primary non-inferiority estimand): 30 mg -0.30% (95% CI -0.51 to -0.09), 60 mg -0.22% (95% CI -0.44 to -0.01), 90 mg -0.40% (95% CI -0.62 to -0.19); non-inferiority met for all three doses (all P<0.0001). Superiority (treatment policy estimand): 90 mg -0.25% (95% CI -0.45 to -0.05; one-sided P=0.0067), 60 mg not significant (P=0.0789).
NCT06672172: OUTSTAND-1 phase 3 T2D trial (placebo-controlled, diet-and-exercise inadequately controlled); enrollment (284) matches this listing exactly. Primary endpoint (HbA1c reduction at Week 32 vs placebo, across 30/60/90mg doses) was met: 1.40-1.68% reduction vs 0.06% for placebo.
VicadrostatPhase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
DA-2811Phase 2Small moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
Tofogliflozin (Apleway / Deberza)Phase 2Small moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
OlorigliflozinPhase 1Small moleculeSGLT2Weak signalNo reviewed efficacy summary in this indication

Large race: only the 73 furthest-along competitors are listed; 77 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Invokana (Canagliflozin) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 2/3Type 2 DiabetesRecruiting
Est. primary completion 2026-12 · NCT05427084 · CT.gov ↗
What to watch
Phase 2Type 2 DiabetesActive not recruiting
Est. primary completion 2026-12-15 · NCT05507892 · CT.gov ↗
What to watch
2027 (4)
January 2027 (1)
Phase 4Chronic Kidney DiseaseNot yet recruiting
Est. primary completion 2027-01-30 · NCT07527390 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Acute Kidney InjuryRecruiting
Est. primary completion 2027-07 · NCT06528405 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Breast Cancer, Breast Cancer Stage IV, Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-10-08 · NCT05090358 · CT.gov ↗
What to watch
Phase 4Acute Ischemic Stroke From Large Vessel OcclusionNot yet recruiting
Est. primary completion 2027-10-31 · NCT06858436 · CT.gov ↗
What to watch
2028 (3)
February 2028 (1)
Phase 2Chronic Kidney DiseaseRecruiting
Est. primary completion 2028-02-28 · NCT06913647 · CT.gov ↗
What to watch
March 2028 (1)
Phase 2Chronic Kidney DiseaseRecruiting
Est. primary completion 2028-03-30 · NCT06182839 · CT.gov ↗
What to watch
July 2028 (1)
Phase 1Solid Tumor, SGLT 2 InhibitorsRecruiting
Est. primary completion 2028-07-31 · NCT07703163 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
Phase 2Endometrioid Endometrial Cancer, Atypical Endometrial HyperplasiaNot yet recruiting
Est. primary completion 2029-01-01 · NCT07890064 · CT.gov ↗
What to watch
March 2029 (1)
Phase 4Type 2 DiabetesEnrolling by invitation
Est. primary completion 2029-03-31 · NCT07547878 · CT.gov ↗
What to watch

See the full readout calendar ↗